Aytu Biopharma (AYTU) Accumulated Expenses (2012 - 2026)

Aytu Biopharma (AYTU) has 15 years of Accumulated Expenses data on file, last reported at $2.7 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 93.43% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 93.43% decrease from a year earlier, with the FY2025 full-year figure at $38.2 million, changed 0.06% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.7 million, down from $40.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for AYTU reached as high as $46.8 million in Q2 2023 and fell as low as $2.7 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $25.1 million across 5 years, with a median of $33.7 million in 2024.
• Across the five-year window, Accumulated Expenses soared 1071.09% in 2024 and sank 93.43% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $41.2 million in 2022, then plunged by 91.84% to $3.4 million in 2023, then surged by 1071.09% to $39.4 million in 2024, then gained by 1.99% to $40.2 million in 2025, then sank by 93.17% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.7 million in Q1 2026, $40.2 million in Q4 2025, and $4.0 million in Q3 2025.